Endothelin (ET) has been shown to be elevated under conditions of cardiac pathology and to produce diverse cardiac effects, including coronary constriction and a positive inotropic influence. We characterized the concentrationand time-dependent effects of the most potent of the ET isoforms, 2, and 4 nmol/L), on myocardial contractility and coronary resistance and assessed its effects on the ischemic and reperfused heart. Because ET-1 has been shown to activate the Na+-H+ exchanger in cardiac myocytes, we determined the contribution of the antiport by examining the effects of ET-1 in the presence of the Na+-H+ exchange inhibitor methylisobutyl amiloride (MIA). At all three concentrations, ET-1 produced an initial positive inotropic effect that was reversed with continued perfusion, the degree of the reversal being dependent on ET-1 concentration. With 0.4 nmol/L, contractility returned to pre-ET-1 values, whereas after 75 minutes of perfusion with 4 nmol/L ET-1, contractility was depressed by 75%. At all concentrations, ET-1 produced a coronary-constricting effect, whereas an elevation in resting tension was observed only with 4 nmol/L ET-1. MIA significantly prevented the positive inotropic effect of ET-1 but had no effect on loss in function or elevation in resting tension produced by 4 nmol/L ET-1. Furthermore, MIA partially, but not significantly, attenuated the constricting effects of all ET-1 concentrations. In the ischemic heart, 0.4 nmol/L ET-1 appeared to delay the loss in contractility produced by cessation of flow, although the effect was not significant. Higher concentrations of ET-1 were without effect on ischemia-induced contractile depression, although their presence produced a marked elevation in resting tension during ischemia that was attenuated by MIA. Recovery in contractility was reduced by all concentrations of ET-1, although the effects of the lowest concentration were associated primarily with defective relaxation. The depressant effects of ET-1 either in normal or ischemic/reperfused hearts were irreversible. The inhibitory effects of ET-1 on contractile recovery were associated with diminished tissue glycogen and elevated lactate levels. High-energy phosphates after reperfusion were depressed in hearts treated with 4 nmol/L ET-1. The attenuation in contractile recovery and alterations in metabolite content were prevented by MIA. These results provide evidence that ET-1 produces complex effects on heart function that are likely mediated via different mechanisms and demonstrate its ability to aggravate ischemic and reperfusion injury through a mechanism possibly involving Na+-H+ exchange activation. (Circ Res. 1994;75:369-378.) Key Words * Na+-H+ exchange * cardiac function a endothelin-1 * energy metabolism * ischemia/reperfusion injury E ndothelins (ETs) are a family of 21 amino acid peptides synthesized by the endothelium that have been shown to play important roles in physiological and pathophysiological processes (see References 1 and 2 for reviews). Although initially discovered in endothelial cells,3 the synthesis of one of the major isoforms, ET-1, has recently been demonstrated in cultured neonatal cardiac myocytes.4 The main properties of ET in the heart include coronary vasconstriction and positive inotropic effects.5-9 ET acts through distinct membrane receptors linked to the production of intracellular messengers, resulting in biological effects.10 In the heart, these effects are associated with phosphoinositide hydrolysis following ET administration.78"1'2 Although it has generally been considered that an elevation in [Ca2]i mediates the vascular constricting effects of ET,13'14 there is evidence that the positive inotropic effect in myocytes occurs in
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Materials and Methods Animals
Male Sprague-Dawley rats weighing between 275 and 325 g were used in the present study. Animals were maintained at the Health Sciences Animal Care Facility of the University of Western Ontario in accordance with the guidelines of the Canadian Council on Animal Care (Ottawa, Ontario).
Heart Perifsions
Rats were killed by decapitation, and hearts were rapidly excised and arranged for retrograde perfusion by the standard Langendorff technique using a nonrecirculating system, essentially as described previously in a report from this laboratory.24 The perfusion buffer was Krebs-Henseleit solution consisting of (mmol/L) NaCl 120, KCl 4.63, KH2PO4 1.17, NaHCO3 20, CaCl2 1.25, MgCl2 1.2, and glucose 8. The solution was gassed with a 95% 02/5% CO2 mixture, and the pH of the solution was 7.4. The entire perfusion system was maintained at 37°C by means of a water-jacketed condenser attached to a circulator. Contractile developed force (apicobasal displacement) was obtained by connecting a force displacement transducer (Grass FT.03) to the apex of the heart at an initial preload stretch of 2 g. The rates of force development (+dF/dt) and relaxation (-dF/dt) were obtained electronically with a Grass differentiator (model 7P20). A side arm off the perfusion cannula was connected to a pressure transducer (Statham Gould P231D) to ascertain changes in coronary vascular resistance. Atria were removed, and hearts were electrically paced at a rate of 5 Hz. Flow rate was maintained with a peristaltic pump at 10 mL/min. All recordings were made with a Grass polygraph.
To initiate total global ischemia, the perfusion pump was turned off for 30 minutes after an initial 30-minute equilibration period. After ischemia, hearts were reperfused by restoring flow to the control level for a further 30 minutes.
Drug Addition Protocols
An initial set of studies was done to determine the concentration-and time-dependent effects of ET-1 (Sigma Chemical Co) on cardiac function. ET-1 at a concentration of either 0.4, 2, or 4 nmol/L was added after a 15-minute equilibration period and perfused for a further 75 minutes. This duration of perfusion with ET-1 was selected because it represented an identical exposure duration with ET-1 in hearts subjected to ischemia and reperfusion, ie, 15-minute equilibration, 30minute ischemia, and 30-minute reperfusion (as noted above). Therefore, for ischemia and reperfusion experiments, the appropriate concentration of ET-1 was added 15 minutes before shutting off flow. To assess the effects of MIA (Research Biochemicals Inc), identical experiments were carried out in the presence of 1 mmol/L of the Na+-H+ inhibitor, which was administered 10 minutes before ET-1 addition. This concentration of MIA was selected on the basis of previous studies in our laboratory demonstrating its efficacy in inhibiting Na+-H+ exchange activity in cardiac myocytes subjected to intracellular acidosis by NH4C1 pulsing.25 In addition, we found that this MIA concentration was without direct effect on cardiac contractility when tested over an 85-minute perfusion period. All drugs were initially dissolved to the highest concentration possible in ethanol. The maximum vehicle ethanol concentration was 0.005%, which was without effect on any parameter when added by itself in control experiments.
Metabolite Assays
For determination of tissue metabolites after reperfusion, the heart was clamped with Wollenberger tongs precooled in liquid nitrogen, removed from the cannula, and stored in liquid nitrogen until the assays were performed. Assays for ATP, ADP, AMP, creatine phosphate, and lactate were performed on 6% perchloric acid extracts. The assay for glycogen was performed with pulverized tissue. Energy metabolite content was determined enzymatically with a Beckman DU-65 spectrophotometer as previously described. 24, 26 Data Analysis Most data were analyzed by a multifactorial ANOVA, followed by the Student-Newman-Keuls test to locate differences between treatment groups. The data reported in Table 2 were analyzed by Student's t test for paired data. Differences were considered significant at the level of P<.05.
Results

Function Nonischemic Hearts
Six hearts in each group were initially studied to determine the time-dependent effects of ET-1 on contractility over a 75-minute perfusion period. At the two lowest concentrations, ET-1 increased developed force to values 131.6±7.4% and 147.2±12% of pre-ET values for 0.4 and 2 nmol/L, respectively, although with both concentrations the positive inotropic effects reversed to values not significantly different from control hearts perfused for identical periods of time in the absence of ET-1 (data not shown). However, with 4 nmol/L ET-1 the reversal in the positive inotropic effect of ET-1 continued with prolonged perfusion such that after 75 minutes of treatment, developed force was reduced to ;25% of values obtained before ET-1 administration (Fig 1, top panel) . It should be noted that the reversal of the initial positive inotropic effect was unlikely to be due to either decomposition of ET-1 or its conversion to a toxic product, since the profile of the cardiac response was consistent with ET-1 containing perfusion buffer used 3 hours after ET-1 addition. MIA significantly prevented the initial positive inotropic effect of 4 nmol/L ET-1. However, it is apparent from Fig 1 ( top panel) that both the magnitude and rate of the negative inotropic effect persisted to extents similar to those seen in the absence of MIA. Although the data are not shown, virtually identical results were obtained with regard to +dF/dt and -dF/dt, with an initial augmentation in both parameters to values 124.1±7.9% and 135.3±9.8% of those found before ET-1 administration, whereas no increase was seen with respect to either parameter in the presence of MIA. However, the de- over, a virtually identical response representing a 20% attenuation in the elevation of coronary pressure by MIA was seen with 0.4 and 2 nmol/L ET-1, although with both concentrations the influence was not significant (data not shown). To explore the possibility that noncoronary factors or insufficient MIA concentration accounted for the inability of MIA to significantly attenuate the coronary constricting effect of ET-1, a number of different approaches were taken. Elevation of the MIA concentration to 10 mmol/L produced a direct negative inotropic effect, although the coronary-constricting effect of 4 nmol/L ET-1 was unaffected. However, even with the high MIA concentration, which is substantially greater than that required to inhibit Na+-H+ exchange, the elevation in coronary pressure was not significantly affected, although a similar trend showing an :20% attenuation by MIA was still present. Moreover, identical effects were seen in hearts that were arrested with 15 mmol/L KCl to remove any potential influence of extravascular factors (data not shown). A number of experiments (n=4) were subsequently done to determine whether the cardiac effects of 4 nmol/L ET-1 could be reversed by restoring normal drug-free perfusion 15 minutes after ET-1 addition. For all parameters, removal of exogenous ET-1 failed to reverse the initial effects. Indeed, with respect to contractility, the loss in function after 15 minutes of ET-1 treatment followed by 15 minutes of normal perfusion was virtually identical to that seen in hearts treated for 30 minutes with ET-1. Thus, after 15 minutes of normal perfusion, developed force, +dF/dt, and -dF/dt were 37.2+8.9%, 403+6.5%, and 38.7±9.0% of pre ET-1 values, respectively. Ischemic and Reperfused Hearts Fig 4 shows the effects of total global ischemia on myocardial developed force in the presence or absence of three different concentrations of ET-1. A total loss in contractility was evident after 150 seconds of ischemia, which was unaffected by either 2 or 4 nmol/L ET-1. Although differences were not significant, with 0.4 nmol/L ET-1, contractility persisted longer, with some function being observed after >400 seconds of ischemia (Fig 4, top panel) . In hearts treated with MIA, the loss in function with or without 4 nmol/L ET-1 was virtually identical, with a total cessation of contractility after 150 seconds of ischemia (data not shown).
Recovery in developed force after reperfusion is shown in Fig 5. ET-1 produced a concentration-dependent inhibition of contractile recovery. Moreover, as shown in Table 1 , 0.4 nmol/L ET-1 produced a marked effect on -dF/dt throughout reperfusion, whereas +dF/dt was significantly diminished at only one time point. However, concentrations of 2 and 4 nmol/L ET-1 produced a marked and significant depression in rates of contraction and relaxation throughout reperfusion (Table 1) .
On its own, MIA failed to influence the degree of recovery, although recovery was more rapid, with significantly higher values being observed after 5 minutes of reperfusion (Table 1 ). As noted above and summarized in Table 1 , the primary modulatory influence of 0.4 nmol/L ET-1 on postischemic recovery was to MIN. OF REPERFUSION significantly depress -dF/dt, with very little effect on other contractile parameters. However, as shown in Table 2 , MIA completely prevented this effect of ET-1, such that -dF/dt was virtually identical to that reported in control hearts (Table 1 ). Fig 6 summarizes the effects of MIA on developed force as well as +dF/dt and -dF/dt in hearts treated with 4 nmol/L ET-1. MIA completely reversed the deleterious effects of 4 nmol/L ET-1 against all parameters. Interestingly, in the presence of MIA and ET-1, recovery was rapid, with a close to 100% restoration in contractility after only 5 minutes of perfusion, compared with a 20% recovery in the other two groups, with a subsequent return to values identical to control. Table 3 shows the effects of various treatments on contracture development in ischemic and reperfused hearts. The elevation in resting tension during ischemia was significantly increased by both 2 and 4 nmol/L ET-1 throughout most of the ischemic period. MIA significantly attenuated the effect produced by 4 nmol/L ET-1. On reperfusion, control hearts responded by a rapid short-lasting elevation in resting tension with a subsequent decrease in resting tension with continued reperfusion. The initial resting tension response to reperfusion was markedly influenced by treatment. Thus, in the presence of MIA, the initial elevation in resting tension was prevented, and values for the first 10 minutes of reperfusion were significantly lower than control values (Table 3) . Interestingly, reperfusion produced an initial rapid reduction in resting tension in hearts treated with subsequent values were found not to be different. However, the presence of MIA with 4 nmol/L ET-1 resulted in resting tension values significantly lower than those found with ET-1 alone throughout the reperfusion period (Table 3) .
We tested whether the inhibitory effects of 4 nmol/L ET-1 on ventricular recovery after reperfusion were reversible by restoring normal ET-free buffer 15 minutes after restoration of flow. Discontinuing ET-1 exposure for 15 minutes after the onset of reperfusion led to recoveries that were higher but not significantly different from those values obtained during continuous 30minute exposure to ET-1 (Table 1 and Fig SC) . Thus, by use of this approach, recovery in developed force, + dF/dt, and -dF/dt after 30 minutes of reperfusion was 26.6±8.9%, 34 .4+7.6%, and 21.5 ±4.8% of preischemic values, respectively (data not shown). No differences in coronary pressures were observed after reperfusion in the presence or absence of ET-1 (Fig 7) . 
Energy Metabolite Content
In nonischemic hearts, none of the treatments had any direct effects on tissue adenine nucleotide or highenergy phosphate contents (data not shown). In reperfused hearts, 4 nmol/L ET-1 reduced both ATP and creatine phosphate levels; this reduction was partially reversed by MIA, particularly in terms of improved creatine phosphate levels (Table 4 ).
In contrast to the lack of direct effect of ET-1 on either high-energy phosphates or adenine nucleotides in normally perfused hearts, the compound increased lactic acid content particularly at 2 and 4 nmol/L, levels Graphs showing the effect of 4 nmol/L endothelin-1 (ET1) on recovery of force (F) and positive and negative dF/dt after reperfusion of ischemic hearts in the absence or presence of methylisobutyl amiloride (MIA). Each point represents mean+SEM and depicts percentage recovery compared with preischemic values. *P< .05 for ET1 alone vs control; +P< .05 for ET1 alone vs MIA+ET1 treatments (n=5; except for control hearts, n=8).
at which the effects were significantly higher than the control value (Fig 9, top panel) . Moreover, the elevation in lactic acid with 4 nmol/L ET-1 also occurred in hearts treated with MIA. Although Fig 9 ( top panel) also suggests a reduction in glycogen by ET-1, differences were found to be not significant. Ischemic hearts reperfused in the presence of ET-1 demonstrated both an elevation in tissue lactate and marked reduction in glycogen levels, although a significant effect of the former was not observed with 0.4 nmol/L ET-1 (Fig 9, bottom panel) . ET-1 (4 nmol/L), which enhanced lactate and depressed glycogen contents in reperfused hearts, failed to exert a significant effect on either metabolite in the presence of MIA when compared with values obtained with MIA only.
Discussion
Since its initial discovery and demonstration of its potent vasoconstrictor properties,3 ET has been extensively studied to determine its effects on the cardiovascular system. In the heart, positive inotropic effects of ET have been well documented, although a precise mechanism underlying this effect remains to be determined. However, it is apparent that ET produces numerous cellular changes in the heart, including elevation in [Ca 2+] ,16 possibly by activation of the voltage-dependent Ca21 current,17 stimulation of phospho-inositide hydrolysis.7,8,11,2 inhibition of adenylate cyclase,12 activation of enzymes including mitogen-activated protein kinase,27 and stimulation of prostaglandin production.5 The relative contribution of these effects to the cardiodynamic effects of ET remain to be investigated; however, there have been suggestions that the effects of ET on the heart may be related to ET concentration, with different concentrations producing distinct cellular responses.8 This type of phenomenon may explain, for example, divergent effects of ET that have been observed with regard to its effects on intracellular Ca2+. For example, in one report, no effect on Ca21 levels was observed with concentrations of ET-1 up to 10 nmol/L,15 whereas in other studies, elevations of [Ca 2±]i and stimulation of the Ca2+ current were seen with ET-1 concentrations of 25 and 20 nmol/L, respectively.16'17 One possible explanation that could account for the dissociation of the positive inotropic effect of ET from elevations in Ca2+ levels may be increased myofilamental sensitivity to Cal±.15 This is supported by a recent report demonstrating that ET-1 stimulates the Na+-H+ exchanger in rat ventricular myocytes, resulting in intracellular alkalinization and increased myofibrillar sensitivity to Cal±.18 Stimulation of the Na+-H+ exchanger by ET could have important consequences toward understanding its potential role in cardiac pathology. For example, it has been demonstrated that addition of ET-1 to ferret papillary muscles exposed to acidotic conditions reversed the negative inotropic effects of acidosis through a Na+-H+ exchange stimulation of increased myofibrillar sensitivity to Ca 2+.20 This important observation could be relevant to furthering our understanding of the mechanisms involved in the cardiodepressant effects of myocardial ischemia. However, it is also important to point out that activation of Na+-H+ exchange could be deleterious to the reperfused myocardium, because the rapid activation of the antiport immediately on reflow could produce a cascade of events resulting in enhanced intracellular Na+ and Ca2+ levels, thus exacerbating reperfusion injury (see Reference 23 for review).
Based on studies linking the Na+-H+ exchange to cardiac effects of ET, the present study was performed first to examine the contribution of the antiport to the contractile effects of ET-1. In addition, we set out to determine whether ET-1 modulates the cardiac response to ischemia and reperfusion and, if so, to examine the role of Na+-H+ exchange by determining the potential modulatory role of the potent Na+-H+ exchange inhibitor MIA. We examined the effects of ET-1 by using an approach that assesses both concentration and time dependence of the compound. Our results demonstrate a transient positive inotropic effect of ET-1 at all three concentrations, with both 2 and 4 nmol/L resulting in a subsequent negative inotropic influence. These results are essentially similar to those reported by Firth et al,6 who used working rat hearts in which the initial elevation in cardiac output by ET-1 was reversed with continued ET-1 perfusion. However, a very low concentration of ET-1 (60 pmol/L), substantially less than used in our study, produced a sustained elevation in cardiac output. Taken together, the results demonstrate the ability of ET-1 to produce either a positive or negative inotropic effect depending on the concentration and duration of exposure. The positive inotropic effect appears to be mediated by the Na+-H+ exchanger, because in our study and others this effect is markedly attenuated by antiport inhibitors. In contrast, the negative inotropic actions of ET-1 and its ability to increase resting tension appear not be related to Na+-H+ exchange, because identical effects of ET-1 were observed in the presence or absence of MIA. These observations support the notion of diverse effects of ET-1 on intracellular homeostasis. Although the precise mechanisms for changes in contractility require further study, a potential explanation for the initial positive inotropic effect may be explained in part by ET-induced stimulation of phosphoinositide hydrolysis resulting in protein kinase C and Na+-H+ exchange activation and in the initial liberation of other mediators such as inositol trisphosphate. Continued perfusion with ET, particularly at high concentrations, has been shown to produce sustained and time-dependent phosphoinositide degradation in both cat and rat cardiac myocytes,8 which could represent the basis for the negative inotropic influence with continued perfusion. Phospholipid degradation could explain, at least in part, the basis for the irreversible nature of the negative inotropic effects of ET-1. With respect to the coronary constricting effects of ET-1, our results with MIA suggest that a component of this effect may be mediated by Na+-H+ exchange as the inhibitor of the antiport consistently produced a 20% reduction, albeit not statistically significant, in ETinduced coronary constriction under numerous experimental conditions (see "Results"). To our knowledge, stimulation of Na+-H+ exchange in vascular tissue by ET-1 has previously not been reported, although it should be noted that this property of ET-1 is not restricted to cardiac tissue; eg, ET-1 has been shown to stimulate the antiport in rabbit renal cortex as well as in rat mesangial cells. 28, 29 Therefore, it is possible that activation of the Na+-H+ exchange may represent a partial contributing mechanism for the constricting effects of ET-1 in addition to its other previously reported effects, such as elevations in [Ca2"]i either via liberation of intracellular stores or enhanced transmembrane Ca2+ influx. 13, 14 We assessed whether ET-1 modulates either the cardiodepressant effects or resting tension elevations during ischemia. These studies extended the previous interesting observation of Wang and Morgan20 that ET could attenuate the cardiodepressant effects associated with acidosis such as which may occur during ischemia. However, it should be emphasized that the approaches differ in that we used rat whole hearts subjected to zero-flow ischemia, whereas Wang and Morgan used ferret papillary muscle exposed to acidic medium. Nonetheless, it is interesting that despite a lack of significant effect, the loss in contractility in the presence of 0.4 nmol/L ET ( Fig 4A) but not 2 or 4 nmol/L ET (Fig 4B and 4C) appeared to be slower compared with the control value and persisted up to 7 minutes after starting ischemia, although under control conditions contractility ceased after 150 seconds. Our studies also demonstrate the ability of ET-1 to inhibit postischemic ventricular recovery even when present at a concentration devoid of direct negative inotropic influence. At that concentration (0.4 nmol/L), inhibition of recovery was manifested primarily by depressed relaxation after reperfusion. This observation suggests that diastolic dysfunction represents the major effect of low ET-1 concentrations in the ischemic and reperfused heart and that ET-1 could interfere with Ca2'-regulatory mechanisms under ischemic and reperfused conditions. In view of the ability of MIA to inhibit the effect of 0.4 nmol/L ET-1 on -dF/dt, one possible explanation for this effect may be Na+-H+ exchange activation by ET-1 using normally perfused rabbit hearts at an ET-1 concentration of 5 nmol/L, although, surprisingly, in that study neither a positive or negative inotropic effect of ET-1 was observed.5 Furthermore, it has very recently been reported that ET-1 infusion in conscious dogs exacerbates diastolic dysfunction after a 10-minute coronary artery occlusion and 60-minute reperfusion. 30 Thus, in that model ET-1 increased the degree of what the authors referred to as "diastolic stunning." Taken together, the evidence strongly suggests that diastolic dysfunction represents an important consequence of ET-1 administration, particularly at low doses or concentrations. Inhibition of contractile dysfunction after reperfusion with ET-1 was not found in the presence of MIA, suggesting that Na+-H+ exchange mediated the deleterious effects of ET-1 after reperfusion. This hypothesis is supported by the now well-established observation that inhibitors of the antiport protect the reperfused myocardium and hence that Na+-H+ exchange plays an important role in mediating tissue injury produced by reperfusion of the ischemic myocardium (see Reference 23 for review). The use of Na+-H+ exchange inhibitors including MIA is somewhat problematic in attempting to determine the role of the antiport in mediating the effects of ET-1 because of their direct protective effects in the absence of other exogenous factors. However, the results support our contention that the protective effects of MIA were related to specific inhibition of ETinduced inhibition of recovery after reperfusion. For example, to diminish this problem we used a relatively short period of ischemia, which on its own resulted in substantial recovery (:'75%) of function after reperfusion. As noted in the results, by use of this duration of ischemia the primary effect of MIA was to accelerate recovery but not to significantly increase its magnitude, a finding previously reported when using amiloride in hearts subjected to 30 or 60 minutes of ischemia followed by reperfusion.31 The important observation in the present report is that ET-1, even at the highest concentrations, failed to exert any deleterious influence in the presence of MIA. Moreover, the ability of MIA to attenuate the depressant effect of 0.4 nmol/L ET-1, a concentration that had no effect on developed force or rate of force development, further suggests a specific action of the drug against ET-induced dysfunction. The salutary effects of MIA against the effects of 4 nmol/L ET-1 were particularly surprising in view of the latter's direct negative inotropic effect at this concentration and the inability of MIA to modulate this influence in normally perfused hearts. Although further studies are required to address this question, it is possible that in hearts subjected to ischemia and reperfusion, changes in intracellular homeostastis such as those involved in ionic regulation may alter the direct response of the heart to ET-1 and unmask a major contributing role of the Na+-H+ exchanger under reperfusion conditions.
As illustrated in Fig 8 and summarized in Table 3 , reperfusion of control hearts or those treated with 0.4 nmol/L ET-1 resulted in the well-established abrupt further elevation in resting tension. However, all hearts treated with either 2 or 4 nmol/L ET-1 showed an immediate reduction in resting tension on reperfusion irrespective of the presence of MIA. The reasons for such differences are uncertain but are unlikely to be associated with the level of resting tension at the end of ischemia, since there were no differences in these values between control hearts and those treated with a combination of 4 nmol/L ET-1 and MIA. Altered Ca2' handling in the presence of high concentrations of ET-1 could account for such differences, although further studies are necessary to define the nature of these possible changes. Although ET-1 produced a reduction in high-energy phosphate content in the reperfused heart that was partially attenuated by MIA, the failure of lower concentrations of ET-1 to inhibit high-energy phosphate stores despite marked inhibition of recovery suggests that this metabolic effect may not represent a key determinant of postischemic recovery in the presence of ET-1. However, in the presence of all concentrations of ET-1, a marked MIA-sensitive reduction in glycogen and an elevation in lactate contents were observed, suggesting a potential association between these metabolites and the deleterious effects of ET-1. The nature of this association and of the mechanistic basis for ET-1-induced metabolic changes requires further studies. A pertinent question relates to the potential clinical relevance of our findings. It has been demonstrated that ischemia and reperfusion upregulate myocardial ET-1 receptors. 21 The existence of ET-1 receptors has been shown in different regions of the human heart.3233 Moreover, elevation of plasma ET levels has been demonstrated in patients with myocardial infarction, 34, 35 although, interestingly, such elevations were not observed with either stable or unstable angina. 35 Stimulation of cardiac ET production has been shown in patients undergoing reperfusion procedures with fibrinolytic agents36 and angioplasty37 as well as in patients after cardiopulmonary bypass. 38 In one of those studies, elevated plasma ET levels have also been shown to be significantly correlated with poor left ventricular function and elevated creatine kinase levels after reperfusion with fibrinolytic agents, leading the authors to conclude that ET may play an important role in the pathogenesis of myocardial infarction processes. 36 Although this remains to be determined with certainty, the present study clearly demonstrates the ability of ET-1 to diminish ventricular function after reperfusion and demonstrates an effective approach to mitigate these actions, at least when using the present model.
